Aliases & Classifications for Keloid Disorder

MalaCards integrated aliases for Keloid Disorder:

Name: Keloid Disorder 75
Keloid 55 17

External Ids:

Summaries for Keloid Disorder

MalaCards based summary : Keloid Disorder, also known as keloid, is related to hypertrophic scars and localized scleroderma. An important gene associated with Keloid Disorder is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Wnt / Hedgehog / Notch and Immune response IFN gamma signaling pathway. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and endothelial, and related phenotypes are digestive/alimentary and skeleton

Wikipedia : 75 Keloid, also known as keloid disorder and keloidal scar, is the formation of a type of scar which,... more...

Related Diseases for Keloid Disorder

Diseases related to Keloid Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 330)
# Related Disease Score Top Affiliating Genes
1 hypertrophic scars 31.1 TGFB1 SMAD3 CD36 BMP6
2 localized scleroderma 30.5 TGFB1 SMAD3
3 scleroderma, familial progressive 30.1 CD36 BMP6
4 peyronie's disease 29.8 TGFB1 SMAD3
5 nephrogenic systemic fibrosis 29.8 TGFB1 SMAD3
6 gingival overgrowth 29.3 TGFB1 CD36
7 pulmonary fibrosis, idiopathic 27.1 TGFB1 SMAD3 SERPINH1 CD36 BMP6
8 keloid formation 12.7
9 torticollis, keloids, cryptorchidism, and renal dysplasia 12.7
10 x-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome 12.2
11 warburg-cinotti syndrome 11.6
12 premature aging syndrome, penttinen type 11.5
13 lobomycosis 11.5
14 pseudofolliculitis barbae 11.5
15 frontometaphyseal dysplasia 2 11.5
16 desmoid tumor 11.2
17 neurofibromatosis, type ii 10.6
18 overgrowth syndrome 10.5
19 systemic scleroderma 10.5
20 skin disease 10.4
21 dowling-degos disease 1 10.4
22 blastomycosis 10.4
23 chromosome 16p13.3 deletion syndrome, proximal 10.3
24 telangiectasis 10.3
25 folliculitis 10.3
26 helix syndrome 10.3
27 basal cell carcinoma 10.3
28 skin atrophy 10.3
29 chromosome 2q35 duplication syndrome 10.2
30 herpes zoster 10.2
31 47,xyy 10.2
32 dermatitis, atopic 10.2
33 dermatitis 10.2
34 cutaneous fibrous histiocytoma 10.2
35 leiomyoma 10.1
36 chickenpox 10.1
37 fibrosis of extraocular muscles, congenital, 1 10.1
38 insulin-like growth factor i 10.1
39 dermatofibrosarcoma protuberans 10.1
40 paracoccidioidomycosis 10.1
41 fibromatosis 10.1
42 hypoxia 10.1
43 rapidly involuting congenital hemangioma 10.1
44 osteochondrosis 10.1 TGFB1 CD36
45 ureteral disease 10.1 TGFB1 SMAD3
46 osteofibrous dysplasia 10.1 TGFB1 CD36
47 breast cancer 10.1
48 bethlem myopathy 1 10.1
49 pemphigus vulgaris, familial 10.1
50 sarcoidosis 1 10.1

Graphical network of the top 20 diseases related to Keloid Disorder:



Diseases related to Keloid Disorder

Symptoms & Phenotypes for Keloid Disorder

MGI Mouse Phenotypes related to Keloid Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.26 CD36 SERPINH1 SMAD3 TGFB1
2 skeleton MP:0005390 9.02 BMP6 CD36 SERPINH1 SMAD3 TGFB1

Drugs & Therapeutics for Keloid Disorder

Drugs for Keloid Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Povidone-iodine Approved Phase 4 25655-41-8
4
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
5
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
6
Ethanol Approved Phase 4 64-17-5 702
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
9
Prilocaine Approved Phase 4 721-50-6 4906
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Verapamil Approved Phase 4 52-53-9 2520
14
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
15 Anti-Infective Agents, Local Phase 4
16 Adjuvants, Immunologic Phase 4
17 Gastrointestinal Agents Phase 4
18 Antiemetics Phase 4
19 HIV Protease Inhibitors Phase 4
20
protease inhibitors Phase 4
21 Antineoplastic Agents, Hormonal Phase 4
22 Autonomic Agents Phase 4
23 BB 1101 Phase 4
24 Chlorhexidine gluconate Phase 4
25 Antimitotic Agents Phase 4
26 Hylan Phase 4
27 Viscosupplements Phase 4
28 Lidocaine, Prilocaine Drug Combination Phase 4
29 Hydrocortisone-17-butyrate Phase 4
30 Hydrocortisone 17-butyrate 21-propionate Phase 4
31 Hydrocortisone hemisuccinate Phase 4
32 Peripheral Nervous System Agents Phase 4
33 Anesthetics Phase 4
34 Anesthetics, Local Phase 4
35 Sodium Channel Blockers Phase 4
36 Diuretics, Potassium Sparing Phase 4
37 Central Nervous System Depressants Phase 4
38 Neurotransmitter Agents Phase 4
39 Neuromuscular Agents Phase 4
40 Cholinergic Agents Phase 4
41 abobotulinumtoxinA Phase 4
42 Acetylcholine Release Inhibitors Phase 4
43 Botulinum Toxins Phase 4
44 Botulinum Toxins, Type A Phase 4
45 Hormone Antagonists Phase 4
46 triamcinolone acetonide Phase 4
47 Triamcinolone hexacetonide Phase 4
48 Triamcinolone diacetate Phase 4
49 Hormones Phase 4
50 Anti-Inflammatory Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease Unknown status NCT01295099 Phase 4 5- fluorouracil;Triamcinolone
2 Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery Unknown status NCT02521402 Phase 4
3 Use of Silicone Gel to Improve Retroauricular Scar in Microtia Patients Unknown status NCT02518035 Phase 4 Silicone Gel
4 Combined Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence.A Randomized Controlled Trial. Completed NCT03239964 Phase 4 Dexamethasone
5 Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars Completed NCT01789346 Phase 4
6 Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study Completed NCT02155439 Phase 4 5-fluorouracil;Triamcinolone
7 A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. Completed NCT00293163 Phase 4
8 Post-Marketing Study of Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color Completed NCT01012388 Phase 4
9 A Prospective, Randomized, Investigator-blinded, Placebo-controlled, Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars Completed NCT00754247 Phase 4 0.5% hydrocortisone, silicone, vitamin E lotion;Onion extract gel;Cetearyl alcohol lotion
10 The Efficacy of Laser Assisted Hair Removal in the Treatment of Acne Keloidalis Nuchae; a Pilot Study Completed NCT01548898 Phase 4
11 A Double Blind Randomized Controlled Trial Comparing the Efficacy of 7% Lidocaine / 7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream for Local Anaesthesia During Laser Treatment of Acne Keloidalis Nuchae and Tattoo Removal Completed NCT02372786 Phase 4 2,5% lidocaine / 2,5% prilocaine cream;7% lidocaine / 7% tetracaine cream
12 Intralesional Injection of Steroids and/or Botulinum Toxin Type A in Hypertrophic Scars and Keloids for Pain Improvement Recruiting NCT03982862 Phase 4 Triamcinolone;Lidocaine;Botulinum toxin A
13 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
14 Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal Terminated NCT01720056 Phase 4 Verapamil;Kenalog 10
15 Effect of Infra-red Diode Laser on Improvement of Surgical Scar and on the Prevention of Excised Keloids Recurrence-Pilot Study Unknown status NCT01158196 Phase 3
16 Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children Unknown status NCT01113125 Phase 3 Betamethason-17-valerate and fusidic acid;Fusidic Acid
17 Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars: a Randomized Controlled Trial Unknown status NCT01861119 Phase 3 Silicone gel Kelo-cort™;;Onion extract gel Contractubex™
18 Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Hypertrophic Scars and Keloids Scars. Completed NCT00993005 Phase 3
19 The Technique of Skin Stretching for Acute Burn Treatment and Scar Reconstruction: Clinical Applications and Working Mechanisms. Completed NCT00609908 Phase 3
20 Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars: 3-arm Trial Recruiting NCT02823236 Phase 3 Topical Pirfenidone;Triamcinolone + Pirfenidone;Intralesional Triamcinolone
21 Phase 2 Of Injectable Collagenase (Xiaflex) For Burns' Associated Contracture Unknown status NCT01237964 Phase 2 Xiaflex (FDA approved collagenase)
22 A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults Completed NCT02079168 Phase 2 RXI-109;Placebo
23 A Prospective, Randomized, Comparative Feasibility Study Evaluating the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Adjunctive to Surgical Scar Revision Completed NCT01446770 Phase 2
24 A Prospective, Randomized, Controlled Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids Completed NCT00587587 Phase 1, Phase 2
25 A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product Following Excision of Keloids Completed NCT00825916 Phase 2 AZX100 Drug Product;AZX100 Drug Product;Placebo
26 A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloids Completed NCT00892723 Phase 2 AZX100 Drug Product;Placebo;AZX100 Drug Product
27 The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study Completed NCT00129428 Phase 1, Phase 2
28 A Single-centre, Double Blind, Randomised, Rising Dose Tolerance Study to Investigate the Safety of Juvista When Administered Following Excision of Ear Lobe Keloids. Completed NCT00469235 Phase 1, Phase 2 Avotermin
29 A Single-centre, Double Blind, Randomised, Tolerance Study to Investigate the Safety of Juvista 500ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids. Completed NCT00710333 Phase 1, Phase 2 Avotermin;placebo
30 A Single-centre, Double Blind, Randomised, Exploratory Study to Explore the Efficacy and Safety of Juvista 250ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids. Completed NCT00836147 Phase 1, Phase 2 Avotermin (Juvista);Placebo
31 Photochemical Tissue Bonding (PTB) for Excisional Wound Healing Completed NCT00586040 Phase 2
32 Open-label, Single-arm Pilot Study of the Effects of Topical 5% Imiquimod Cream on Preventing Keloid Recurrence After Surgical Keloidectomy Recruiting NCT03760250 Phase 2 Imiquimod 5% cream
33 A Phase 2, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of MRG-201 Following Intradermal Injection in Subjects With a History of Keloids Active, not recruiting NCT03601052 Phase 2 Remlarsen;Placebo
34 Phase II Trial of Sorafenib in Patients With Extensive Keloids Terminated NCT01425216 Phase 2 Sorafenib
35 A Therapeutic Trial of Intralesional Bevacizumab in Patients With Non-pedunculated Keloids Terminated NCT01408953 Phase 2
36 A Post-shave Keloid Recurrence Study in Two Parts: A Biomarker Assessment Followed by a Randomized, Double-blind, Placebo Controlled Evaluation of Safety, Tolerability, and Efficacy of QAX576 Terminated NCT00987545 Phase 2 QAX576;QAX576 placebo
37 A Prospective, Randomized, Double-blinded Comparison of the Use of 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts. Terminated NCT02705352 Phase 2 5-Fluorouracil
38 Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars Withdrawn NCT02546076 Phase 2
39 Calcium Electroporation for the Treatment of Keloids Unknown status NCT01941914 Phase 1 Calcium chloride
40 Phase I Study of High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin Completed NCT02630303 Phase 1
41 Transperineal Injection of Cross-linked Hyaluronan Gel Into Anterior Perirectal Fat to Reduce Rectal Toxicity From High Dose Rate Brachytherapy and/or Intensity-Modulated Radiation Therapy for Prostate Cancer Completed NCT00882232 Phase 1
42 Radiotherapy to Prevent Fibrosis After Lumbar Laminectomy Completed NCT00018876 Phase 1
43 Randomized Single-center, Single-blind, Two-arm Parallel Group Trial of Using MEBO™ Dressing Versus Standard Care at Zagazig University Hospital in the Management of Donor and Recipient Sites of Split-thickness Skin Graft Recruiting NCT02737943 Phase 1 Moist Exposed Burn Ointment (MEBO);Zagazig
44 A Randomised Open Label Placebo Controlled Study to Evaluate Fractional Collagen Synthesis in Keloids and Identify Biomarkers of Keloid Biology for Potential Application in Future Clinical Trials Terminated NCT01978301 Phase 1 Triamcinolone acetonide;Placebo
45 Microcyn Scar Management HydroGel, K103163 vs. Kelo-cote® Scar Gel for the Management of Hypertrophic or Keloid Scars Unknown status NCT01736969
46 Prospective, Controlled Study of the Efficacy of NdYag for Acne Keloidalis Nuchae Unknown status NCT00757315 Topical corticosteroid alone
47 Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage for Standardised Total Ear Reconstruction Unknown status NCT00565552 Silicone gel (Dermatix®)
48 Comparison of the Blister Fluid Components of Second Degree Burned Patients With the Blister Fluid Components Following Intralesional Cryosurgery of Keloid Scars - A Feasibility Study. Unknown status NCT01627769
49 Comparison of the Effectiveness in Prevention of Hypertrophic Scars or Keloids Between Silicone Sheet, Silicone Gel and Paper Steri-strip-A Randomised Controlled Trial. Unknown status NCT00849004
50 A Prospective Comparison of Robotic and Endoscopic SMG Resection Via Retroauricular Approach Unknown status NCT01726907

Search NIH Clinical Center for Keloid Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Betamethasone
Bupivacaine
Dexamethasone
Triamcinolone

Genetic Tests for Keloid Disorder

Anatomical Context for Keloid Disorder

MalaCards organs/tissues related to Keloid Disorder:

41
Skin, Breast, Endothelial, Bone, Prostate, Thyroid, Heart

Publications for Keloid Disorder

Articles related to Keloid Disorder:

(show top 50) (show all 2922)
# Title Authors PMID Year
1
Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars. 9 38
20428796 2010
2
Syndecan-2 and decorin: proteoglycans with a difference--implications in keloid pathogenesis. 9 38
20386290 2010
3
Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. 9 38
19772524 2010
4
Topical tamoxifen therapy in hypertrophic scars or keloids in burns. 9 38
19636578 2010
5
Elastic fiber assembly is disrupted by excessive accumulation of chondroitin sulfate in the human dermal fibrotic disease, keloid. 9 38
19879246 2009
6
Keloid scarring: new treatments ahead. 9 38
20096165 2009
7
Human embryonic stem cell-derived mesoderm-like epithelium transitions to mesenchymal progenitor cells. 9 38
19196144 2009
8
Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid. 9 38
19546682 2009
9
Low decorin expression along with inherent activation of ERK1,2 in ear lobe keloids. 9 38
19268470 2009
10
[Expression of Smads in keloid scarring]. 9 38
19781253 2009
11
Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. 9 38
19289101 2009
12
Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression. 9 38
19438747 2009
13
[The effect of tunicamycin on Fas protein expression and its function in fibroblasts from hypertrophic scar and keloid]. 9 38
19803206 2009
14
Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. 9 38
19037237 2009
15
Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. 9 38
19120328 2009
16
Keloid scarring: bench and bedside. 9 38
19360429 2009
17
[Expression and function of sphingosine kinases 1 and 2 in human keloid fibroblasts]. 9 38
19567073 2009
18
Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts. 9 38
18787533 2009
19
[Comparison of the mechanisms of intralesional steroid, interferon or verapamil injection in the treatment of proliferative scars]. 9 38
19408724 2009
20
Keloidal basal cell carcinoma: not a distinctive clinicopathological entity. 9 38
18795924 2009
21
Basic fibroblast growth factor: a potential new therapeutic tool for the treatment of hypertrophic and keloid scars. 9 38
19071002 2009
22
Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts. 9 38
18832570 2008
23
Keloid banding using suture ligature: a novel technique and review of literature. 9 38
18978483 2008
24
Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. 9 38
18463684 2008
25
The use of corticosteroids to treat keloids: a review. 9 38
18611924 2008
26
DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. 9 38
18406579 2008
27
[The expression of fibrillin 1 in pathologic scars and its significance]. 9 38
19119630 2008
28
TGF-beta1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts. 9 38
18575776 2008
29
Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. 9 38
17943180 2008
30
Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture. 9 38
18087663 2008
31
[The role of cell pathway in apoptosis of fibroblasts from proliferative scar induced by steroid or IFN]. 9 38
18437985 2008
32
Targeting of Sp1 transcription factor: a novel therapeutic approach for keloids, an in vitro analysis. 9 38
18031462 2007
33
Increased CCN2 transcription in keloid fibroblasts requires cooperativity between AP-1 and SMAD binding sites. 9 38
17968183 2007
34
Transforming growth factor beta (TGFbeta) and keloid disease. 9 38
17660136 2007
35
Effect of heat shock protein 47 on collagen accumulation in keloid fibroblast cells. 9 38
17535221 2007
36
[The expression of periostin in hyperplasic scars and the relations to TGF-beta1 and its receptors]. 9 38
17649947 2007
37
Fas-mediated apoptotic signal transduction in keloid and hypertrophic scar. 9 38
17440345 2007
38
Flashlamp pulsed-dye laser suppressed TGF-beta1 expression and proliferation in cultured keloid fibroblasts is mediated by MAPK pathway. 9 38
17457842 2007
39
Exogenous nitric oxide stimulated collagen type I expression and TGF-beta1 production in keloid fibroblasts by a cGMP-dependent manner. 9 38
17052928 2007
40
[Discoidin domain receptors (DDRs) expression in pathological scar fibroblast formation]. 9 38
17554880 2007
41
Induction of TIMP-1 and HSP47 synthesis in primary keloid fibroblasts by exogenous nitric oxide. 9 38
17145168 2007
42
Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. 9 38
17889631 2007
43
Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. 9 38
16841034 2006
44
Modulation of collagen synthesis in keloid fibroblasts by silencing Smad2 with siRNA. 9 38
17051103 2006
45
[Expressions of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids]. 9 38
17144456 2006
46
Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. 9 38
16705627 2006
47
Elevated prolidase activity in keloids: correlation with type I collagen turnover. 9 38
16634881 2006
48
Upregulation of TGF-beta1 expression may be necessary but is not sufficient for excessive scarring. 9 38
16498396 2006
49
[Relationship between the proliferation and immunoinduction of epithelial cells and the destruction of hair follicles and sebaceous glands in keloids]. 9 38
16736611 2006
50
P38 MAP kinase mediates transforming growth factor-beta2 transcription in human keloid fibroblasts. 9 38
16467496 2006

Variations for Keloid Disorder

Expression for Keloid Disorder

Search GEO for disease gene expression data for Keloid Disorder.

Pathways for Keloid Disorder

Pathways related to Keloid Disorder according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 11.8 TGFB1 SMAD3 BMP6
2
Show member pathways
11.67 TGFB1 SMAD3 BMP6
3 11.6 TGFB1 SMAD3
4 11.57 TGFB1 SMAD3
5
Show member pathways
11.55 TGFB1 SMAD3
6 11.52 TGFB1 SMAD3 BMP6
7 11.52 TGFB1 SMAD3 BMP6
8
Show member pathways
11.46 TGFB1 SMAD3
9 11.42 TGFB1 SMAD3
10 11.41 TGFB1 CD36
11
Show member pathways
11.39 TGFB1 SMAD3
12 11.36 TGFB1 SMAD3
13 11.29 TGFB1 SMAD3
14 11.23 TGFB1 SMAD3 BMP6
15 11.22 TGFB1 SMAD3
16 11.2 TGFB1 SMAD3
17 11.15 TGFB1 CD36
18 11.1 TGFB1 SMAD3 BMP6
19 10.91 TGFB1 SMAD3
20 10.66 TGFB1 SMAD3
21 10.61 TGFB1 SERPINH1 BMP6

GO Terms for Keloid Disorder

Biological processes related to Keloid Disorder according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.83 SMAD3 CD36 BMP6
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.83 TGFB1 SMAD3 CD36 BMP6
3 positive regulation of gene expression GO:0010628 9.82 TGFB1 SMAD3 CD36
4 wound healing GO:0042060 9.67 TGFB1 SMAD3
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.66 TGFB1 CD36
6 cellular response to mechanical stimulus GO:0071260 9.65 TGFB1 BMP6
7 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.65 TGFB1 SMAD3
8 positive regulation of epithelial cell proliferation GO:0050679 9.64 TGFB1 BMP6
9 cellular response to transforming growth factor beta stimulus GO:0071560 9.64 TGFB1 SMAD3
10 regulation of MAPK cascade GO:0043408 9.63 TGFB1 BMP6
11 cell development GO:0048468 9.63 TGFB1 BMP6
12 T cell activation GO:0042110 9.62 TGFB1 SMAD3
13 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.62 TGFB1 BMP6
14 negative regulation of fat cell differentiation GO:0045599 9.61 TGFB1 SMAD3
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.61 TGFB1 SMAD3
16 extrinsic apoptotic signaling pathway GO:0097191 9.6 TGFB1 SMAD3
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.59 SMAD3 CD36
18 ureteric bud development GO:0001657 9.58 TGFB1 SMAD3
19 positive regulation of protein secretion GO:0050714 9.58 TGFB1 BMP6
20 negative regulation of mitotic cell cycle GO:0045930 9.57 TGFB1 SMAD3
21 positive regulation of protein import into nucleus GO:0042307 9.56 TGFB1 SMAD3
22 endoderm development GO:0007492 9.55 TGFB1 SMAD3
23 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.54 TGFB1 SMAD3
24 cell-cell junction organization GO:0045216 9.51 TGFB1 SMAD3
25 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.49 TGFB1 SMAD3
26 positive regulation of chondrocyte differentiation GO:0032332 9.48 SMAD3 BMP6
27 lens fiber cell differentiation GO:0070306 9.46 TGFB1 SMAD3
28 positive regulation of SMAD protein signal transduction GO:0060391 9.43 TGFB1 BMP6
29 SMAD protein complex assembly GO:0007183 9.4 TGFB1 SMAD3
30 positive regulation of extracellular matrix assembly GO:1901203 9.37 TGFB1 SMAD3
31 SMAD protein signal transduction GO:0060395 9.33 TGFB1 SMAD3 BMP6
32 regulation of striated muscle tissue development GO:0016202 9.32 TGFB1 SMAD3
33 regulation of binding GO:0051098 9.26 TGFB1 SMAD3
34 evasion or tolerance of host defenses by virus GO:0019049 8.96 TGFB1 SMAD3
35 positive regulation of bone mineralization GO:0030501 8.8 TGFB1 SMAD3 BMP6

Molecular functions related to Keloid Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.33 TGFB1 SMAD3 BMP6
2 collagen binding GO:0005518 8.96 SMAD3 SERPINH1
3 transforming growth factor beta receptor binding GO:0005160 8.8 TGFB1 SMAD3 BMP6

Sources for Keloid Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....